SEC Form 4 · accession 0001387131-16-005710
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert B Rothermel
Director
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 25, 2016 | A | 100,000 | $0.00 | A | 127,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $8.46 | May 25, 2016 | A | 30,000 | A | — | May 25, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The shares being reported are being issued pursuant to restricted stock units (RSUs), each one of which represents a contingent right to receive one share of the issuer's common stock. The RSUs vest on the seventh anniversary of the grant date provided that the Reporting Person has continued to provide services to the Company during such period. The RSUs are granted pursuant to the Company's 2009 Equity Incentive Plan and are subject to other provisions as are set forth in the RSU agreement relating to such grant under the plan.
- F2The option vests monthly over a period of twelve months commencing on the grant date. The option is granted pursuant to the Company's 2009 Equity Incentive Plan and is subject to other provisions as are set forth in the option agreement relating to such grant under the plan.